Is host heparanase required for the rapid spread of heparan sulfate binding viruses?

Mayank Khanna*, Charani Ranasinghe, Anna M. Browne, Jin Ping Li, Israel Vlodavsky, Christopher R. Parish

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    14 Citations (Scopus)

    Abstract

    Vaccinia virus (VACV), like many other viruses, binds to cell surface heparan sulfate (HS) prior to infecting cells. Since HS is ubiquitously expressed extracellularly, it seemed likely that VACV-HS interaction may impede virus spread, with host heparanase, the only known mammalian endoglycosidase that can degrade HS, potentially overcoming this problem. In support of this hypothesis, we found that, compared to wild type, mice deficient in heparanase showed a 1–3 days delay in the spread of VACV to distant organs, such as ovaries, following intranasal inoculation, or to ovaries and spleen following intramuscular inoculation. These delays in spread occurred despite heparanase deficiency having no effect on VACV replication at inoculation sites. Subsequent in vitro studies revealed that heparanase treatment released VACV from HS expressing, but not HS deficient, infected cell monolayers. Collectively these data suggest that VACV relies on host heparanase to degrade HS in order to spread to distant sites.

    Original languageEnglish
    Pages (from-to)1-6
    Number of pages6
    JournalVirology
    Volume529
    DOIs
    Publication statusPublished - Mar 2019

    Fingerprint

    Dive into the research topics of 'Is host heparanase required for the rapid spread of heparan sulfate binding viruses?'. Together they form a unique fingerprint.

    Cite this